Νέα 2011

Dr. Kouzi

Offered Tests Table

GENETIC FACTORS FOR THROMBOPHILIA

Molecurar test of the genes: F5 (Factor V Leiden) (1691G>A) & 4044A>G)

F2 (Factor II) or prothrombin (G20210A)

MTHFR (C677T)

GENETIC FACTORS FOR CARDIOVASCULAR DISEASES

Molecular testing of 13 genes for 17 mutations:

1. F5 (Factor V-Leiden) (2 mutations)
2. F2 (Factor II) - prothrombin (1 mutation)
3. MTHFR (2 mutations)
4. F13b (Factor XIII) (1 mutation)
5. FGB (1 mutation)
6. ITGB3 ή GpIIIa ή HPA1 (1 mutation)
7. PAI-1 (1 mutation)
8. ACE (1 mutation)
9. Apo B (1 mutation)
10. ApoΕ (Ε2/Ε3/Ε4) haplotype study
11. eNOS (2 mutations)
12. LTA (1 mutation)
13. PROCR (EPCR) (2 mutations)

GENETIC FACTORS FOR ATHEROSCLEROSIS

Molecular testing of 7 genes for 10 mutations:

1. Apo B (1 mutation)
2. ApoΕ (Ε2/Ε3/Ε4) haplotype study
3. FGB (1 mutation)
4. eNOS (2 mutations)
5. ITGB3 ή GpIIIa ή HPA1 (1 mutation)
6. ACE (1 mutation)
7. LTA (1 mutation)

GENETIC FACTORS FOR THROMBOEMBOLISM

Molecular testing of 6 genes for 7 mutations:

1. F5 (Factor V-Leiden) (2 mutations)
2. F2 (Factor II) - prothrombin (1 mutation)
3. MTHFR (2 mutations)
4. F13b (Factor XIII) (1 mutation)
5. PAI-1 (1 mutation)
6. PROCR (EPCR) (2 mutations)

GENETIC FACTORS FOR ALZHEIMER DISEASE

Molecular testing of ApoE gene (Ε2/Ε3/Ε4)

IMMUNOGENETIC FACTORS FOR DISEASE PREDISPOSITION

Molecular testing of the allele of HLA Β-27

PHARMACOGENOMICS – PERSONALIZED TREATMENT

1.Molecular testing for the detection of genotypes in the DPD, associated with the patient’s response to treatment with 5-FU (5-fluorouracil): a) Allele 2 (IVS1G>A) – 1 polymorphism and b) Alleles *3, *4, *5A, *7, *8, *9, *10, *12, *13, Μ166V, R886Η, D949V.

2.Molecular testing for the detection of genotypes in the UDP gene, associated with the patient’s response to treatment with Irinotecan (or Camptosar).

3.Molecular testing for the detection of the alleles 1, 2, 3A, 3C in TMPT gene, associated with the patient’s response to treatment with sulfapyridine.

4.Molecular testing for the detection of the alleles *3, *4, *5, *6, *7, *8, *9, *14, *19 and *ΧΝ, associated with CYP2D6 gene, which metabolizes 25% of the prescribed drugs.

5.Molecular testing for the detection of 34 alleles in CYP2D6/CYP2C19 genes, that metabolize 40% of the prescribed drugs.

6.Molecular testing for the detection of the alleles *2, *2B, *3, *4, *5, *6, *7, *8, *9, *10, *11, associated with CYP2C19 gene, which metabolizes 15% of the prescribed drugs.

7.a) Molecular testing for the detection and identification of VCORC-1 (1639G>A) - 1 polymorphismand CYP2C9-2*(430C>T), CYP2C9-3*(1075A>C) – 2 polymorphisms, that are associated with the response to anti-coagulation treatment Warfarin and b) Molecular testing for the detection of the alleles *2, *3, *4, *5, *6, *11, associated with CYP2C9 gene, which metabolizes 5-10% of the prescribed drugs.

VIRUS MOLECULAR DETECTION

1. Qualitative detection of cytomegalovirus (CMV)

2. Quantitative detection of cytomegalovirus (CMV)

3. Qualitative detection of Epstein Barr Virus (EBV)

4. Detection of (Varicella Zoster virus -VZV)

5. Detection and typing of Herpes Simplex Virus 1 & 2 (HSV), using Real Time PCR

6. Qualitative and quantitative detection of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV), using Real Time PCR in serum

7. Detection and genotyping of 24 types of Human Papilloma Virus (HPV), using Microarrays.

MOLECULAR DETECTION OF BACTERIA, PARASITES AND GENITAL INFECTIONS

1. DNA detection of Mycoplasma hominis

2. DNA detection of Chlamydia trachomatis

3. DNA detection of Ureoplasma pavum/urealyticum

4. DNA detection of Group Β Streptococcus

5. DNA detection of Toxoplasma gondii

6. DNA detection of Mycoplasma genitalium

7. DNA detection of Neisseria gonorrhoeae

Molecular Analysis of Hereditary Diseases

1. 1. Haemochromatosis (HH)

Molecular analysis of genes: HFE (12 mutations)

TFR2 (4 mutations)

FPN1 (2 mutations)

Also the HAMP gene can be tested and the whole sequence of HFE gene.

1. 2. Cystic Fibrosis (CF)
2. 3. Mediterranean Fever (FMF)

Molecular analysis of CFTR gene (36 mutations) and R1158X & E822X mutations with PCR in total blood.

Analysis of 200 mutations of CFTR gene.

Also the whole sequence of CFTR can be tested.

Molecular analysis of MEFV gene (12 mutations)

4. B-Thalasemia

Molecular analysis of the b-globulin gene (22 mutations)

Whole sequence of the gene.

5. A-Thalasemia (Hb-H)

Molecular analysis of a-globulin gene (21 mutations)

Molecular analysis of HBA₁ and ΗΒΑ₂ genes

Examples of additional single- and multi-factor diseases

1. Angiotensin 1, AGT
2. Hemorrhagic Telangiectasia Syndrome, I and II
3. Hemophilia A and B
4. Acatalasemia
5. Amyotrophic lateral sclerosis
6. alpha-1-antitrypsin deficiency
7. Fructose intolerance
8. Adenosine deaminase deficiency)
9. 17-beta-hydroxysteroid-dehydrogenase 3 deficiency)
10. 21-hydroxylase deficiency
11. Ectodermal dysplasia
12. Apolipoprotein B
13. Apolipoprotein E
14. Glycogen storage disease
15. Αrrhythmogenic right ventricular dysplasia, familial
16. Alzheimer disease
17. Charcot-Marie-Tooth disease
18. Fabry disease
19. Gaucher disease
20. Lou Gehrig disease
21. Amyotrophic lateral sclerosis
22. Niemann-Pick Disease
23. Norrie disease
24. Parkinson’ disease
25. Pompe disease
26. Tay Sachs disease
27. Wilson disease
28. Ataxia telangiectasia
29. Achondroplasia
30. Galactosaemia
31. Glaucoma
32. Dilated Cardiomyopathy
33. Sickle cell anaemia)
34. Systemic lupus erythematosus
35. Cystinuria
36. Cystinosis
37. Lactose intolerance
38. Xeroderma pigmentosum
39. Retinitis Pigmentosa
40. Metachromatic leucodystrophy
41. Muscular dystrophy Duchenne/Becker
42. Myotonia congenita
43. Myotonic dystrophy
44. Neurofibromatosis type 1and II
45. Maple Syroup Urine Disease
46. Spinal muscular atrophy
47. Familial Mediterranean fever
48. Familial hypercholesterolemia
49. Τuberous sclerosis
50. Homocystinuria
51. Pancreatitis, hereditary
52. Polycystic kidney disease
53. Spinal and bulbar muscular atrophy
54. APCR.
55. Retinoblastoma
56. Rheumatoid arthritis
57. Diabetes, type I, II & MODY
58. Severe combined immunodeficiency
59. Angelman syndrome
60. Bloom syndrome
61. Gorlin-Goltz syndrome or Nevoid basal cell carcinoma syndrome = NBCCS or Basal Cell nevus Syndrome BCNS
62. Lesch – Nyhan syndrome
63. Louis Bar syndrome
64. Lynch syndrome
65. Nail - patella syndrome
66. Prader Willi syndrome
67. Rett syndrome
68. Rubinstein-Taybi syndrome
69. Sanfilippo C syndrome
70. Smith-Lemli-Opitz syndrome
71. Usher syndrome
72. Von Hippel-Landau Syndrome
73. Wolfram syndrome
74. Tyrosinemia
75. Hyperliproteinemia
76. Adrenal hyperplasia, congenital due to 21 hydroxylase deficiency
77. Hypertrophic cardiomyopathy
78. Familial hypercholesterolemia
79. Ectodermal dysplasia, Hypohidrotic or Anhidrotic, or Christ-Siemens-Touraine Syndrome, or CST syndrome
80. Short stature
81. Phenylketonuria
82. Huntingtons disease

Dr. Koliakos

THE REAL STORY OF LITTLE ATHANASIOS

Little Athanasios was born after a very difficult and long natural labour, because he was overweight. The middle cerebral artery was thromboses and his brain was deprived of oxygen for a long time. This condition led to cerebral palsy. He was the forth child of the family and the family, who wanted to help all its children, decided to cryopreserve Athanasios umbilical cord blood, just in case. At that moment they did not realise that one day these cells would be very helpful for someone in the family. Soon after his birth, Athanasios presented signs of cerebral palsy and the family started treatment using all the known methods. At age of 20 months his mother was informed that a child with the same as Athanasios’ problems was treated in the USA by using its own stem cells that her family had preserved during her birth. The mother remembered that she had cryopreserved Athanasios cells and asked Biohellenika if Athanasios could be a candidate to take his cells. Since then a long procedure started: Biohellenika and Duke University exchanged information about stem cells banking and medical records. Finally after making all the preliminary tests the family and the cells were transferred to Duke University for the infusion. The family stayed in the USA for 4 days and Athanasios was infused with his own stem cells. The procedure was executed safely and without any side-effect. Later Athanasios came back and reported regularly to the neurologists that took care of him during his stay in Duke University. The stem cells were cryopreserved in 3 cryovials. All the quality controls after post-thaw were done in Biohellenika’s labs. The viability of the cells was 96% and for this reason Athanasios took only the cells from two of the cryovials. The third remains in Duke University for future use in case it is needed. Having experience from the first child treated, we expect improvement after three months.

The University of Georgia announced that it will start a clinical trial with 40 children with cerebral palsy that have cryopreserved their own stem cells in collaboration with a private cord blood bank. The trial will include children until 8 years old that already have cryopreserved umbilical cord blood stem cells. At the moment the treatment includes only autologous use of stem cells, even in the case of fully matched sibling donor.

---

Danae’s real story.

Autologous administration of stem cells, stored by Biohellenika for the treatment of Danae who suffered from cerebral palsy.

Biohellenika administered an umbilical cold blood stem cell sample to a 31 month old child suffering from cerebral palsy. This autologous administration is a unique success for Biohellenika, the largest Family Bank in Greece, since it is the first unit of cord blood that has been cryopreserved in a Greek bank and administered successfully from a University Hematology clinic of USA.

The cerebral palsy was caused due to complications during birth, resulting to the insufficient oxygen supply to Danae’s brain for sometime and the baby presented problems in muscle tone and strength during the first months of its life. The family addressed Biohellenika directly and the head of the scientific board Dr. Kouzi-Koliakou communicated with the Hematology clinic of Duke University USA.

Biohellenika sent the complete file of cryopreservation of the baby’s placenta blood to the clinic. The file was examined closely and approved by the doctors of the clinic. Then, the medical team requested the transport of the child and the sample. The initial blood collection by the obstetrician was enough, although it was a twin birth. This had as a result the number of the cryopreserved stem cells to be sufficient for transplantation. The stem cells administered to the child were analogous to a double of the weight the child had. In autologous use the administration of a large number of stem cells is useful for the patient, as it has a better therapeutic outcome and there is no fear of rejection, as the child uses its own stem cells that are completely compatible.

The stem cells were sent in a special transfer container that is called Voyager. The stem cells can safely remain in the Voyager up to 23 days, a period which is sufficient for transport to any place of the world.

The stem cells were cryopreserved in five cryo-vials. Two of them contained a smaller volume for quality tests before the thawing. The total number of stem cells the vial contained was more than enough.

The administration of the stem cells was scheduled for 28/7/09. A day before the transplantation the child was examined by a neurologists’ team that assessed and logged all clinical findings for future reference. All cryo-vials were thawed and the cells were administered to the child intravenous and under the surveillance of all its vital signs. The child did not present any complications during the administration of the cells that lasted 10 minutes. Immediately after the transplantation, the family left the hospital and came back the following day for a new check up from the doctors. The following day they left the hospital and today they are in Greece. Continuous improvement in the movement, speech and communication is noted every day. The child remained in USA only three days, treated as outpatient and didn’t pass any night in the hospital.

According to the experience of the doctors a significant improvement of the movement, decrease of the muscle spasticity and improvement in communication is expected after the third month. Up to day the child has presented clear signs of improvement as she is now able to speech more fluently, communicate with her family, stay and walk and generally she has more confidence in starting and finishing actions.

The administration of the cells was safe and no side effects were noticed to Danae. Biohellenika cryopreserves clear nucleated cells, after almost full depletion of red blood cells, so the amount of cryoprotectant DMSO is very low. Because of that the side effects like vomiting, nausea and changes in the blood pressure are very rare. The child during the whole procedure was completely calm and cheerful.

Larger volume of the cryopreserved sample, needs larger amount of the cryo-protectant DMSO, thus the side effects are stronger. In Biohellenika the stem cells are cryopreserved in cryo-vials were a pure population of stem cells is stored, without impurities of red blood cells. This has as a result a smaller cryopreserved volume and therefore no unwanted side effects to the patients during administration.

The opportunity given to this family is due to the mother’s foresight, who persisted on new year’s eve to receive Biohellenika’s collection kit by any means, to the doctor’s conscientiousness who performed two big cord blood collections from the babies that were twins and born with a cesarean, something very difficult many times, and to Biohellenika’s personnel that on new year’s eve processed with the best possible way a sample that justified every ones efforts. All data lab obtained after the thawing of the sample in the laboratories of the Transplantation Unit of Dukes University showed a large number of cells of high grade of survival, clear from bacteria and viruses and with an intense capability of proliferation. The chances of improvement of the young patient are very high. Up until today Biohellenika has administered with success more than 30 samples to patients for different diseases.

On 26^th of January another child with the same problem will take the same way for treatment.

---

DALLAS HEXTELL

Stem cells from Dallas umbilical cord blood were the only hope for the family, stated Cynthia Hextell, Dallas mother, who was suffered from cerebral palsy since birth and transplanted with its own stem cells. The family never forgets the day that Dallas was diagnosed with cerebral palsy. It was tragic, Dallas did not even sit nor had sight and the only way for him to communicate was endless crying. Soon after birth the parents realized that something was wrong with Dallas. Fortunately Dextells had cryopreserved Dallas umbilical cord blood stem cells, for just in case and they never believed that they will be used in the future, because of Dallas sickness. Their decision then was proved valuable and wised today. On the age of 18 months old Dallas received its cells by a simple procedure. Retells did not know what they will expect from this treatment, but fortunately they did not wait for along. Dallas therapist, Polly Harlan noticed serious changes soon after the transplantation. The first signs of Dallas improvement were the participation in family’s life, fillings expression and speech development. Lately he starts to stand, walk smile and be happy. Moreover he became a real boy. For Cynthia it was a miracle. The results were so impressive and fast and stem cells gave to Dallas and his family the opportunity for a real life.

Doctors now are looking to expand the therapeutic applications of stem cells to others cases like Dallas. According to Dr David Harris, Professor of Immunology in Arizona University “ stem cells from the umbilical cord blood is the new hope for the children with cerebral palsy, since they have the ability to insert into brain’’ Retells family is grateful for their decision to bank Dallas stem cells, since this action gave them a hope for Dallas future. In cerebral palsy, as a result of shortage in oxygen, the child’s umbilical cord blood stem cells can improve its life, when they were infused during the first two years of life.

Hextells family wants to inform the future parents for the benefits of stem cells banking, because nobody knows when they can be used

---

KEEGAN & KELDAN D0HENEY

Your son suffers from ‘’leukaemia‘’. It is very painful for somebody to hear this diagnosis, but Wendy Doheney had to hear two times. The first time Keegan was just two years old. Doctors initially put Keegan’s leukaemia in remission, and Doheneys were a little happy. The second time was three years later. ‘’Keegan was in school, kindergarten, and me in home’’ Wendy remembers. ‘’And suddenly I had this filling, that something was going wrong. I called the Keegan’s doctor, expressed my filling and she thought that I lost my mind. There were no sign of wondering, but just simply I knew. Unfortunately Wendy’s instinct was proved right and keegan’s leukaemia return. Fortunately this time Doheneys had cryopreserved the little brother’s Keldan umbilical cord stem cell. If siblings were histocompatible, then Keldan’s stem cells would be use to treat Keegan’s leukaemia. ‘’We were so relieved, because we banked Keldan’s stem cells’’ Wendy remembered. ‘’When I was pregnant we had be informed about stem cells and all the ‘’miracles’’ that happen by using them. We examine all the possibilities and we decided to bank, for just in case. The good news came very soon. The boys were compatible. The doctors transplanted Keldan’s stem cells to Keegan body and now Keegan is healthy, more than nine years. An excellent student and athlete, Keegan has a very special bond to his little brother Keldan. ‘’ My little brother saved my life’’ said. Because of him now I am here, alive.

---

When Chloe Levine was 9-months-old, her parents noticed she couldn’t hold her bottle with her right hand.

That wasn’t her only developmental setback. Chloe, of Pinetop, Ariz., was unable to raise both hands above her head, and she could not crawl.

At 12 months, a CAT scan showed a portion of the left side of Chloe’s brain had not developed and contained fluid. Seeking answers, Chloe’s parents, Ryan and Jenny Levine took their daughter to a neurologist who diagnosed the toddler with right-side hemiplegic cerebral palsy.

“The cerebral palsy had only affected the right side of her body,” Jenny Levine said Monday morning on FOX & Friends. “The neurologist told us we were looking at 17, 18 years of therapy.”

Click here to watch Dr. Manny Alvarez, managing health editor of FOXNews.com, speak with the Levines on FOX & Friends.That was when the Levines heard about an experimental procedure at Duke University in North Carolina where children with cerebral palsy were infused with their own cord blood stem cells in an effort to heal and repair damaged brain tissue.The Levine’s remembered they had banked Chole’s cord blood when she was born.“It was a miracle,” Alvarez said Monday on FOX & Friends. “I congratulate you for banking her cord blood. Stem cells are a new field of medicine and they certainly can rejuvenate the tissue.”Two months ago, Chloe, 2, received an infusion of her own stem cells and her progress is remarkable, said her father, Ryan Levine.“Her therapist said she’s made a 50 percent recovery,” he said. “She can walk, run, and do sign language with her right hand.”“It’s a miracle,” agreed Jenny Levine. “To hear your baby’s voice is a gift.”Alvarez said all parents expecting babies should consider cord blood banking.“There is no downside, this is material we used to throw away,” he said. “And while the blood is most useful for the child it came from, it can sometimes be used for siblings. This is a science that is evolving more and more.”Storing cord blood costs about $2,000, but Alvarez said he expects the price to come down in the near future. Cerebral palsy refers to any one of a number of neurological disorders that appear in infancy or early childhood and permanently affect body movement and muscle coordination but don’t worsen over time, according to the National Institute of Neurological Disorders and Stroke. It is caused by abnormalities in the parts of the brain that control muscle movements.

Dr. Koliakos

Each child comes in the world with a gift from the nature, with a “life insurance”, with a quantity of “spare parts of cells” which if are preserved they will contribute for the health and its long life. (Roger Schort 2005)

Each child is endued with a supply of stem cells which can be used at some time for the safekeeping of its health, the improvement of quality or the extension of its life.

The birth of your child is a unique chance to preserve this valuable material. Do not take away from him/her this chance. The possibility to use the stem cells which are cryo-preserved at birth,  nowadays it comes up to 1/400 for the child itself.

The use of stem cells apart from the child itself can also be extended to the parents, the siblings, as long as the tissue-compatibility is checked. So the up-to-date possibility for the graft to be used for a member of the family comes up to 1/200.

We have to notice that according to nowadays medical data the possibility which is bigger to 1/250 although is small can not be considered as negligible.

 

ASH Annual Meeting Abstracts) 2005 106: Abstract 1330
http://www.parentsguidecordblood.com/content/usa/medical/medmotiv.shtml?navid=20

This possibility has been calculated considering the nowadays approved applications without including the applications of regenerating medicine which are in the phase of clinical trials.

It is known that in the umbilical cord blood there is a category of cells which can be multiplied and transformed, so that they can replace cells of any tissue (Koegler et al 2003).  The geometrical increase of the approved publications related to new applications admits the prediction of use all of the samples which are cryo-preserved.
For this reason our company thinks for sure that almost all the samples of the stem cells which are cryo-preserved today in liquid nitrogen one day in the future will be asked  for use, consequently it takes care so that the thousands of children whose grafts are kept in our facilities, one day will be grateful to their parents for their precaution.

 

Biohellenika recommends to the expectant parents before they decide to keep the stem cells from the umbilical cord blood and before they choose the company for the cryo-preservation of the valuable material, to visit for their information, independent web-sites especially the ones which were created by parents or unions of parents abroad such as: www.parentsguidecordblood.com and www.cordblooddonor.org.

Read about pro and con of the umbilical cord blood preservation in:
http://www.parentsguidecordblood.com/content/usa/medical/medmotiv.shtml?navid=20

The Cord Blood forum (http://www.cordbloodforum.org/index_flash.html) contains information of the up-to-date medical application of the cells which are coming from the umbilical cord blood.

---

The umbilical cord blood contains the biggest quantity of any other source of stem cells, can be collected at the natural birth but at the cesarean too, and it is once in a lifetime opportunity to collect these cells. The procedure for the collection begins just after the end of the labor and the cut of the umbilical cord, so it can do no harm mother or the baby. The collection of the umbilical cord blood is performed by puncturing the umbilical cord after local antisepsis. From this blood stem cells are separated, frozen and kept in liquid nitrogen conditions in minus 196˚ C indefinitely.
The stem cells can be used for the therapy of over 50 diseases.

Dr. Koliakos

Because the choice of a company for collection and storage of your stem cells is a serious decision, to make it easier for you, we have written the following important questions before your final choice.

1. Has the bank been certified and inspected from a public authority?
2. Does the company work legally in Greece?
3. Does it collaborate with a hospital or a big research center?
4. The process, the quality controls and the storage of the sample is performed in the company’s own laboratories?
5. The equipment that are used in the laboratories are specially designed for the use of stem cell samples or are they used to perform other medical tests or other cells storage?
6. The reagents and the equipment that are used have the label CE and are they designed exclusively for human use?
7. Have stem cells that have been stored by the bank been used for a transplantation and what was the result?
8. What happens in the case of sample’s contamination or small volume?
9. Is the collection kit of the sample easy and safe to use from the obstetrician/nurse? Are they prepared in the case of premature birth?
10. What measures have been taken in the case of company’s bankruptcy?
11. Is the staff of the company available any time to answer all your queries or solve any problem before, during, or after the collection of the sample?
12. is the cost of the process-storage of the sample within logical bound? Is there the possibility of a financial settlement?
13. Is the cost of the services stable the next 20 years or there is a possibility to rise?
14. In the case of inability of the parents to pay directly the company, what will be the consequences for the sample and the process of its storage?
15. In case of twin birth or when the storage is performed for a second child of the family is there any discount?
16. How the company guarantees the safe transport of the sample from the hospital to the laboratories and how long it is take?
17. Does the company provide support to the parents in the case of illness of the child from a serious disease that could be treated with the stored stem cells?
18. Is there a guidance in case of illness and are the parents constantly informed for the new areas if stem cell applications?

REASONS TO CHOOSE BIOHELLENIKA FOR YOUR BABY STEM CELLS COLLECTION AND PRESERVATION

• Biohellenika is an AABB (American Association of Blood Banks) accredited company that ensures the quality and the acceptance of stored cells in hospitals all over the world for autologous or family treatment.

• It is the first private company in Greece that is licensed by the National Transplant Organization

• Biohellenika is accredited by the National Accreditation System (ESYD) for all tests that must be done in stem cells and mother’s blood for a successful cryopreservation and treatment.

• Biohellenika provides double storage facilities in its labs in Athens and Thessaloniki for safety reasons and for emergency treatments. So every patient can reach his/her sample immediately.

• Proceeds the whole length of umbilical cord and give the clients the highest number of mesenchymal stem cells, ready to use. This procedure is protected by the patent No 1007490. According to this method there is no need of cell proliferation, to increase the number of cells, a procedure that is not permitted at first by the law, needs time to be accomplished, it is not safe and the quality of cells after proliferation is different than the initial.

• Biohellenika does not cryopreserve the umbilical cord in pieces, but at first extract the cells from the total length and then preserve the cells in more vials, ready to use up on the request.

• Provide a second selection of hematopoietic stem cells directly from placenta after perfusion, a method that is protected by the patent No 1007478). By this second selection a double number of haematopoietic stem cells stored that is enough to treat overweight patients with malignant diseases and also for more than one use.

• Biohellenika uses an AABB accredited Traceability system, ISBT 128, that follows the sample after enrolment and ensures a safe treatment.

• All samples are tested for microbe contamination and in case of detection the cells are treated with the appropriate antibiotics.

• All cord blood samples and mother’s blood are tested for virus contamination of hepatitis B, C, HIV and CMV by PCR method and the mother it is not necessary to repeat these tests six months later.

• Biohellenika inform parents after procedure with the appropriate medical document that describes the total number of nucleated cells, the haematopoietic and mesenchymal stem cells, by flow cytometry, microbiology and virology tests.

• Biohellenika pryopreserves the stem cells in multiple cryovials, integrally attached, system protected by the patent 1007483, that permits each time to use the appropriate number of cells.

• 805 autologous treatments with the stem cells that are stored in Biohellenika’s labs have been successfully completed up to now.

• According to article 3 of the Private Agreement that signed by Biohellenika and parents for the 20 years storage, Biohellenika provides the cells in 48 hours after a written request.

• Biohellenika provides free medical consultation until the expiration date of the Private Agreement by a highest quality team of Academic Doctors.